Altered Neuregulin1 (NRG1) expression and NRG1/ErbB4 signaling are implicated in schizophrenia and temporal lobe epilepsy pathogenesis, however limited research has been done with respect to their role in epilepsy. Our study on HA-Nrg1-tg mice that overexpress the cysteine-rich domain of NRG1-type III, revealed diverse recurrent epileptic seizures characterized by spike and wave discharges (SWDs) in the cortex and thalamus. Seizure expression varied among animals, with slow (4 – 5 Hz) and/or fast (6 - 8 Hz) SWDs present. Slow 4-5 Hz SWDs occurred during passive wakefulness and were abundant during slow-wave sleep (SWS), resembling status epilepticus. All epileptiform activity ceased for an hour after ethosuximide (ETX) injection (200 mg/kg), a known absence epilepsy medication. Conversely, the mGlu5 receptor positive allosteric modulator VU 0360172 (10 mg/kg; s.c) increased SWD frequency and duration but in a small sample size (n=3). HA-Nrg1-tg mice exhibited abnormal sleep LFP, with power spectral analysis showing reduced delta (1-4 Hz) and gamma (30-100 Hz) frequencies and increased theta and spindle frequency (4-12 Hz) oscillations compared to wildtypes.In conclusion, our findings highlight NRG1's involvement in epileptogenesis, suggesting potential therapeutic targets for epilepsy management. Aberrant sleep LFP patterns underscore the impact of NRG1 dysregulation on neuronal network dynamics, offering insights into epilepsy mechanisms and potential therapeutic interventions targeting NRG1 signaling pathways.